🇺🇸 FDA
Pipeline program

VAY736, Placebo Solution for injection or infusion 0 mg/1 mL

CCFZ533H12201BC

Phase 2 small_molecule active

Quick answer

VAY736, Placebo Solution for injection or infusion 0 mg/1 mL for Moderate to severe hidradenitis suppurativa is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Ophthalmics Europe
Indication
Moderate to severe hidradenitis suppurativa
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials